{"filing":{"accession_number":"0001193125-26-267465","cik":"0001826457","ticker":"GLUE","company_name":"Monte Rosa Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"glue-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526267465/glue-20260611.htm"},"events":[{"id":5349,"run_id":4686,"accession_number":"0001193125-26-267465","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte \u0026 Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6219,"accession_number":"0001193125-26-267465","item_number":"5.07","item_title":"Submission of Matters to Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte \u0026 Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:02:08.558418+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6219,"accession_number":"0001193125-26-267465","item_number":"5.07","item_title":"Submission of Matters to Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte \u0026 Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:02:08.558418+00:00","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-06-11"}]}